BACKGROUND: Fms-like tyrosine kinase-3 (FLT3) gene mutations are frequent in acute promyelocytic leukemia but their prognostic value is not well established. DESIGN AND METHODS: We evaluated FLT3-internal tandem duplication and FLT3-D835 mutations in patients treated with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent trials of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) and Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005. RESULTS: FLT3-internal tandem duplication and FLT3-D835 mutation status was available for 306 (41%) and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) patients had internal tandem duplication and D835 mutations, respectively. Internal tandem duplication was correlated with higher white blood cell and blast counts, lactate dehydrogenase, relapse-risk score, fever, hemorrhage, coagulopathy, BCR3 isoform, M3 variant subtype, and expression of CD2, CD34, human leukocyte antigen-DR, and CD11b surface antigens. The FLT3-D835 mutation was not significantly associated with any clinical or biological characteristic. Univariate analysis showed higher relapse and lower survival rates in patients with a FLT3-internal tandem duplication, while no impact was observed in relation to FLT3-D835. The prognostic value of the FLT3-internal tandem duplication was not retained in the multivariate analysis. CONCLUSIONS: FLT3-internal tandem duplication mutations are associated with several hematologic features in acute promyelocytic leukemia, in particular with high white blood cell counts, but we were unable to demonstrate an independent prognostic value in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
BACKGROUND:Fms-like tyrosine kinase-3 (FLT3) gene mutations are frequent in acute promyelocytic leukemia but their prognostic value is not well established. DESIGN AND METHODS: We evaluated FLT3-internal tandem duplication and FLT3-D835 mutations in patients treated with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent trials of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) and Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005. RESULTS:FLT3-internal tandem duplication and FLT3-D835 mutation status was available for 306 (41%) and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) patients had internal tandem duplication and D835 mutations, respectively. Internal tandem duplication was correlated with higher white blood cell and blast counts, lactate dehydrogenase, relapse-risk score, fever, hemorrhage, coagulopathy, BCR3 isoform, M3 variant subtype, and expression of CD2, CD34, human leukocyte antigen-DR, and CD11b surface antigens. The FLT3-D835 mutation was not significantly associated with any clinical or biological characteristic. Univariate analysis showed higher relapse and lower survival rates in patients with a FLT3-internal tandem duplication, while no impact was observed in relation to FLT3-D835. The prognostic value of the FLT3-internal tandem duplication was not retained in the multivariate analysis. CONCLUSIONS:FLT3-internal tandem duplication mutations are associated with several hematologic features in acute promyelocytic leukemia, in particular with high white blood cell counts, but we were unable to demonstrate an independent prognostic value in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Authors: Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: M A Sanz; G Martín; C Rayón; J Esteve; M González; J Díaz-Mediavilla; P Bolufer; E Barragán; M J Terol; J D González; D Colomer; C Chillón; C Rivas; T Gómez; J M Ribera; R Bornstein; J Román; M J Calasanz; J Arias; C Alvarez; F Ramos; G Debén Journal: Blood Date: 1999-11-01 Impact factor: 22.113
Authors: S P Whitman; K J Archer; L Feng; C Baldus; B Becknell; B D Carlson; A J Carroll; K Mrózek; J W Vardiman; S L George; J E Kolitz; R A Larson; C D Bloomfield; M A Caligiuri Journal: Cancer Res Date: 2001-10-01 Impact factor: 12.701
Authors: J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen Journal: Leukemia Date: 2003-12 Impact factor: 11.528
Authors: Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Maria Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann Journal: Blood Date: 2002-07-01 Impact factor: 22.113
Authors: Isabel Moreno; Guillermo Martín; Pascual Bolufer; Eva Barragán; Eva Rueda; José Román; Pascual Fernández; Pilar León; Armando Mena; José Cervera; Antonio Torres; Miguel A Sanz Journal: Haematologica Date: 2003-01 Impact factor: 9.941
Authors: N I Noguera; M Breccia; M Divona; D Diverio; V Costa; S De Santis; G Avvisati; M B Pinazzi; M C Petti; F Mandelli; F Lo Coco Journal: Leukemia Date: 2002-11 Impact factor: 11.528
Authors: Harry Iland; Ken Bradstock; John Seymour; Mark Hertzberg; Andrew Grigg; Kerry Taylor; John Catalano; Paul Cannell; Noemi Horvath; Sandra Deveridge; Peter Browett; Tim Brighton; Li Chong; Francisca Springall; Juliet Ayling; Alberto Catalano; Shane Supple; Marnie Collins; Juliana Di Iulio; John Reynolds Journal: Haematologica Date: 2011-10-11 Impact factor: 9.941
Authors: Miguel A Sanz; Pierre Fenaux; Martin S Tallman; Elihu H Estey; Bob Löwenberg; Tomoki Naoe; Eva Lengfelder; Hartmut Döhner; Alan K Burnett; Sai-Juan Chen; Vikram Mathews; Harry Iland; Eduardo Rego; Hagop Kantarjian; Lionel Adès; Giuseppe Avvisati; Pau Montesinos; Uwe Platzbecker; Farhad Ravandi; Nigel H Russell; Francesco Lo-Coco Journal: Blood Date: 2019-02-25 Impact factor: 22.113
Authors: Robert E Gallagher; Barry K Moser; Janis Racevskis; Xavier Poiré; Clara D Bloomfield; Andrew J Carroll; Rhett P Ketterling; Diane Roulston; Esther Schachter-Tokarz; Da-Cheng Zhou; I-Ming L Chen; Richard Harvey; Greg Koval; Dorie A Sher; James H Feusner; Martin S Tallman; Richard A Larson; Bayard L Powell; Frederick R Appelbaum; Elisabeth Paietta; Cheryl L Willman; Wendy Stock Journal: Blood Date: 2012-06-25 Impact factor: 22.113
Authors: Antonio R Lucena-Araujo; Juan L Coelho-Silva; Diego A Pereira-Martins; Douglas R Silveira; Luisa C Koury; Raul A M Melo; Rosane Bittencourt; Katia Pagnano; Ricardo Pasquini; Elenaide C Nunes; Evandro M Fagundes; Ana B Gloria; Fábio Kerbauy; Maria de Lourdes Chauffaille; Israel Bendit; Vanderson Rocha; Armand Keating; Martin S Tallman; Raul C Ribeiro; Richard Dillon; Arnold Ganser; Bob Löwenberg; P J M Valk; Francesco Lo-Coco; Miguel A Sanz; Nancy Berliner; Eduardo M Rego Journal: Blood Date: 2019-07-10 Impact factor: 22.113